Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants

Abstract Polypharmacy is common in patients with atrial fibrillation (AF), making these patients vulnerable to the occurrence of potential drug-drug interactions (DDIs). We assessed the risk of ischemic stroke and major bleeding in the context of concomitant treatment with potential DDIs in patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ji Yun Lee, Il-Young Oh, Ju-Hyeon Lee, Seok Kim, Jihoon Cho, Charg Hyun Park, Sooyoung Yoo, Soo-Mee Bang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/856f9fe1d01b4f1cab52d854094efa05
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:856f9fe1d01b4f1cab52d854094efa05
record_format	dspace
spelling	oai:doaj.org-article:856f9fe1d01b4f1cab52d854094efa052021-11-21T12:18:08ZDrug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants10.1038/s41598-021-01786-22045-2322https://doaj.org/article/856f9fe1d01b4f1cab52d854094efa052021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01786-2https://doaj.org/toc/2045-2322Abstract Polypharmacy is common in patients with atrial fibrillation (AF), making these patients vulnerable to the occurrence of potential drug-drug interactions (DDIs). We assessed the risk of ischemic stroke and major bleeding in the context of concomitant treatment with potential DDIs in patients with AF prescribed direct oral anticoagulants (DOACs). Using the common data model (CDM) based on an electronic health record (EHR) database, we included new users of DOACs from among patients treated for AF between January 2014 and December 2017 (n = 1938). The median age was 72 years, and 61.8% of the patients were males, with 28.2% of the patients having a CHA2DS2-VASc score in category 0–1, 49.4% in category 2–3, and 22.4% in category ≥ 4. The CHA2DS2-VASc score was significantly associated with ischemic stroke occurrence and hospitalization for major bleeding. Multiple logistic regression analysis showed that increased risk of ischemic stroke and hospitalization for major bleeding was associated with the number of DDIs regardless of comorbidities: ≥ 2 DDIs was associated with ischemic stroke (OR = 18.68; 95% CI, 6.22–55.27, P < 0.001) and hospitalization for major bleeding (OR = 5.01; 95% CI, 1.11–16.62, P < 0.001). DDIs can cause reduced antithrombotic efficacy or increased risk of bleeding in AF patients prescribed DOACs.Ji Yun LeeIl-Young OhJu-Hyeon LeeSeok KimJihoon ChoCharg Hyun ParkSooyoung YooSoo-Mee BangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ji Yun Lee Il-Young Oh Ju-Hyeon Lee Seok Kim Jihoon Cho Charg Hyun Park Sooyoung Yoo Soo-Mee Bang Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
description	Abstract Polypharmacy is common in patients with atrial fibrillation (AF), making these patients vulnerable to the occurrence of potential drug-drug interactions (DDIs). We assessed the risk of ischemic stroke and major bleeding in the context of concomitant treatment with potential DDIs in patients with AF prescribed direct oral anticoagulants (DOACs). Using the common data model (CDM) based on an electronic health record (EHR) database, we included new users of DOACs from among patients treated for AF between January 2014 and December 2017 (n = 1938). The median age was 72 years, and 61.8% of the patients were males, with 28.2% of the patients having a CHA2DS2-VASc score in category 0–1, 49.4% in category 2–3, and 22.4% in category ≥ 4. The CHA2DS2-VASc score was significantly associated with ischemic stroke occurrence and hospitalization for major bleeding. Multiple logistic regression analysis showed that increased risk of ischemic stroke and hospitalization for major bleeding was associated with the number of DDIs regardless of comorbidities: ≥ 2 DDIs was associated with ischemic stroke (OR = 18.68; 95% CI, 6.22–55.27, P < 0.001) and hospitalization for major bleeding (OR = 5.01; 95% CI, 1.11–16.62, P < 0.001). DDIs can cause reduced antithrombotic efficacy or increased risk of bleeding in AF patients prescribed DOACs.
format	article
author	Ji Yun Lee Il-Young Oh Ju-Hyeon Lee Seok Kim Jihoon Cho Charg Hyun Park Sooyoung Yoo Soo-Mee Bang
author_facet	Ji Yun Lee Il-Young Oh Ju-Hyeon Lee Seok Kim Jihoon Cho Charg Hyun Park Sooyoung Yoo Soo-Mee Bang
author_sort	Ji Yun Lee
title	Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
title_short	Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
title_full	Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
title_fullStr	Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
title_full_unstemmed	Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
title_sort	drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/856f9fe1d01b4f1cab52d854094efa05
work_keys_str_mv	AT jiyunlee drugdruginteractionsinatrialfibrillationpatientsreceivingdirectoralanticoagulants AT ilyoungoh drugdruginteractionsinatrialfibrillationpatientsreceivingdirectoralanticoagulants AT juhyeonlee drugdruginteractionsinatrialfibrillationpatientsreceivingdirectoralanticoagulants AT seokkim drugdruginteractionsinatrialfibrillationpatientsreceivingdirectoralanticoagulants AT jihooncho drugdruginteractionsinatrialfibrillationpatientsreceivingdirectoralanticoagulants AT charghyunpark drugdruginteractionsinatrialfibrillationpatientsreceivingdirectoralanticoagulants AT sooyoungyoo drugdruginteractionsinatrialfibrillationpatientsreceivingdirectoralanticoagulants AT soomeebang drugdruginteractionsinatrialfibrillationpatientsreceivingdirectoralanticoagulants
_version_	1718419075887005696

Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants

Ejemplares similares